iBio, Inc.

Climate Impact & Sustainability Data (2022, 2024)

Substantial doubt exists related to our ability to operate as a going concern.
We have incurred and expect to continue to incur significant losses.
We anticipate that our expenses will increase in the future.
We need additional funding to fully execute our business plan.
The actual amount of funds we will need to operate is subject to many risk factors.
Raising additional capital may cause dilution to our existing stockholders and/or restrict our operations or rights.
We currently have no products approved for commercial sale.
We have a limited experience operating as a CDMO or biopharmaceutical.
Potential use of government funding for R&D programs may impose conditions limiting our ability to take certain actions.

We are evaluating a number of potential options to expand our cash runway, including lowering our burn rate, asset sales or licenses, raising capital, and grant revenue or collaborations.
We are reviewing our pipeline and making portfolio decisions to focus resources on promising areas.